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Abstract: Long-acting injectable antipsychotics (LAIs) were developed to make treatment 
easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-
generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting 
formulation. The purpose of this review is to evaluate the available literature concerning the 
impact of SGA-LAIs on patient functioning and quality of life (QOL). Although several studies 
regarding schizophrenia patients’ functioning and QOL have been performed, the quantity of 
available data still varies greatly depending on the SGA-LAI under investigation. After reviewing 
the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or 
QOL of patients with schizophrenia, as compared with placebo. However, while methodological 
design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, 
the significant amount of evidence in recently published research demonstrates the beneficial 
influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over 
oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking 
in several aspects that may help physicians in choosing the correct drug therapy. Meaningful 
differences have been observed between SGA-LAIs in the onset of their clinical efficacy and 
in the relationships between symptoms and functioning scores. Moreover, head-to-head studies 
comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning 
are available mainly on risperidone LAI, while those comparing olanzapine LAI with other SGA-
LAIs are still lacking. Lastly, some data on their use, especially in first-episode or recent-onset 
schizophrenia and in refractory or treatment-resistant schizophrenia, is available.
Keywords: outcome, first-episode schizophrenia, recent-onset schizophrenia, treatment resis-
tant schizophrenia
Introduction
The World Health Organization classifies schizophrenia among the top ten causes of years 
lost due to its disability.1 This is caused by its specific onset in early adulthood and long-
term persistence or sudden mutation of symptoms in at least two-thirds of patients.2
Most patients are unable to reach at least one milestone, such as being in a stable 
relationship, having full-time competitive employment, or having self-supported inde-
pendent living. A review of eight controlled trials has highlighted the fact that rates 
of unemployment for patients with schizophrenia, although they have good support, 
ranged from only 30% to 80%, with a median of 60% across these studies,3 even in 
the context that the majority of them frequently expressed their keenness to work.4,5 
Otherwise, rates of marriage for patients with schizophrenia were reported to range 
from about 5% to 30%, with the majority ranging between 15% and 30%.6–12
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The early phase of schizophrenia, including the first 
2 years up to 5 years after the onset, is thought to be essential 
in determining long-term prognosis.13
Symptomatic relapse in schizophrenia can be destructive: 
the setback can be dramatic, often leading to increased use of 
outpatient services14 and resulting in hospitalization.6,14,15 In 
addition, relapse can be strictly connected with a biological 
risk. It has been hypothesized that active psychosis reflects 
a period of disease progression to the extent that patients 
may not come back to their previous level of function and 
treatment refractoriness may be evident.16,17
Poor adherence is considered to be the most frequent cause 
of relapse in schizophrenia.18,19 When patients discontinue their 
medications, even after the first episode, the risk for symptom-
atic relapse increases dramatically, by nearly five times.20
In clinical settings, poor compliance is common, espe-
cially in the early stages of the disease,21–24 with between 
40% and 60% of patients with schizophrenia partially or 
totally noncompliant with oral antipsychotics,25,26 and no 
real difference between first-generation antipsychotics and 
second-generation antipsychotics (SGA) was found.27 The 
Clinical Antipsychotic Trials of Intervention Effectiveness 
study has highlighted that up to 74% of people affected by 
schizophrenia start to discontinue their medications after 
18 months; also, the European First Episode Schizophrenia 
Trial found that up to 42% of patients stopped their therapy 
within 1 year after the first psychotic episode.28,29
Nonadherence has a wide variation, probably due to 
differences in the targeted population, definitions, and 
measurement methods. However, it has been noticed that 
studies using more strict measurement methodology, such 
as pill count, electronic monitoring, and blood drug level, 
often indicate higher levels of nonadherence.30–33 Moreover, 
the duration of follow-up certainly has a clear influence on 
the observed frequencies of nonadherence. Therefore, for 
different reasons, it is reasonable to consider that adherence 
is much lower in routine care than in clinical trials.34
Managing nonadherence must be patient specific. Usu-
ally it needs quite a few strategies; however, shared decision 
making between the patient and physician is virtually always 
involved. Long-acting injectable antipsychotics (LAIs) were 
developed to make treatment easier and enhance adherence 
and/or signal the physician when nonadherence occurs.35
Current guidelines
Majority of the available guidelines and algorithms (with the 
exception of The Schizophrenia Patient Outcomes Research 
Team (PORT) project, 2009) recommend LAIs for patients 
who need maintenance treatment and express a preference for 
them over oral antipsychotics, and/or when it is necessary to 
improve adherence to medication,36–39 with a few guidelines 
factually suggesting a switch from oral antipsychotics to 
LAIs during maintenance treatment.40,41
However, the Texas Medication Algorithm Project for 
antipsychotics in schizophrenia42 and the Canadian guidelines 
recommend LAIs in all phases of schizophrenia, also in the 
first 2–5 years.43 Lastly, the French Association for Biological 
Psychiatry and Neuropsychopharmacology recommends LAI 
as first-line treatment to patients with schizophrenia during 
maintenance treatment.44
Efficacy/effectiveness of LAIs versus 
oral antipsychotics
Although LAIs have been developed to enhance adherence 
and/or signal the physician when nonadherence occurs, evi-
dence regarding their superiority over oral antipsychotics in 
terms of relapse prevention is ambivalent and also depends 
on trial design. Even though a meta-analysis has shown a 
significant benefit of LAI versus oral antipsychotics,45 two 
recent meta-analyses of randomized controlled trials (RCTs) 
have highlighted both LAIs and oral antipsychotics were 
effective in relapse prevention and hospitalization.46,47 Two 
large RCTs have shown a longer time to relapse with an LAI 
versus oral antipsychotics.48,49
Relevant advantages of LAIs versus oral antipsychotics 
in reducing psychiatric hospitalization have been shown by 
a recent meta-analysis performed by Kishimoto et al50 on 
25 mirror-image studies. However, the authors admit that 
mirror-image studies may also be biased by the fact that 
treatment status is not blinded, thresholds for hospitalization 
can modify over time, and patients always start LAI after 
a period of time in which although oral antipsychotics are 
taken daily, the outcomes are considered suboptimal. It has 
also been noted that reverse mirror-image studies (ie, from 
LAI to oral formulation) are lacking.
The majority of cohort studies detected lower hospi-
talization rates and/or longer time to discontinuation with 
LAI, even though several studies noted equivalent or better 
outcomes for oral medication, and a prescribing/channeling 
bias in cohort studies suggests that patients treated with LAI 
have a more severe stage of illness.
Moreover, it has been hypothesized that oral antipsy-
chotics may be as effective as LAIs when adherence and 
bioequivalence are secured, which appears plausible because 
LAIs are designed to mimic the pharmacokinetics of oral 
compounds in adherent patients.51
In their recent review, Haddad et al35 concluded that 
strengths and weaknesses are inherent in each of the three 
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different study designs. The typical RCTs cannot necessarily 
be the best way to evaluate treatments that are considered use-
ful in reducing nonadherence, because of selective recruitment 
of more adherent patients and they can also modify ecology of 
the treatment. Treatment is not carried out in a setting in which 
real-world conditions are preserved. Otherwise, weaknesses 
of observational studies involve lack of blinding and difficulty 
estimating the effectiveness of treatment without considering 
confounders and prescribing bias. The best approach to evalu-
ate comparative effectiveness can be alternative “effectiveness 
trials” more closely resembling real life. An ideal solution 
should involve different aspects: trials should be prospective, 
should be performed at several sites, should use broad inclu-
sion criteria, without requiring a lot of data, should be focused 
on patients in an early phase of disease, and should follow 
patients for at least 2 years using relapse and/or hospitalization 
as the primary outcome measures.51
LAi, patient functioning, and quality of life
Although patients with schizophrenia treated with LAIs 
demonstrated symptomatic improvement, the improvement 
is not always associated with functional improvement.52–55 
It has been shown that in patients with stable schizophre-
nia, compliance is mainly related to recognition of the 
positive effects of the pharmacological therapy on daily 
life.56,57 In particular, during long-term therapies, subjective 
perception of general wellness and quality of life (QOL) 
are clear factors influencing and maintaining compliance 
to treatment.58 Consequently, a significant role has been 
assigned recently to the notion of subjective well-being and 
QOL, even in patients treated with antipsychotics.59 Well-
known additional factors determining poor compliance are: 
side effects (mainly extrapyramidal symptoms), complex 
treatment plans, and misunderstanding of dosage schemes.60 
Considering that the introduction of SGA partially reduced 
the incidence of side effects, the development of LAIs should 
further simplify the dosage plans, thus reducing mistakes and 
improving the regular intake of medications.61 It seems clear 
that SGA-LAIs seem to put together the advantages of SGA 
with a long-acting formulation.62
Thus, the purpose of this paper is to review the available 
literature regarding SGA-LAIs, evaluating patient function-
ing and QOL.
Materials and methods
An electronic search was conducted through Medline and 
PubMed to identify articles relevant to the role of SGA-
LAIs on patient functioning and QOL in schizophrenia. 
Keywords used were “second-generation long-acting 
injectable antipsychotics”, “second-generation depot”, “social 
functioning”, “quality of life”, “risperidone long-acting”, 
“paliperidone long-acting”, “olanzapine long-acting”, 
“aripiprazole long-acting”, “schizophrenia”, “first-episode 
schizophrenia”, “recent onset schizophrenia”, “refractory 
schizophrenia”, and “treatment-resistant schizophrenia”. This 
procedure was supplemented with a manual search of the 
bibliography included in the articles found, and of relevant 
reviews, in order to gain access to additional references. 
Studies with vaguely described interventions or inadequate 
outcome information were excluded. The methodological 
quality of the studies was assessed according to the following 
variables: diagnostic criteria used, demographic representation 
of indicators, study design (eg, sample size, control groups, 
direct vs indirect assessment), assessor’s characteristics 
(eg, bias and blindness), and assessment tools (eg, outcome 
measures). The design of a study was considered “controlled” 
when treatments were comparatively evaluated.
We identified 60 English language articles published 
between January 1998 (when the first SGA-LAI was 
launched) and December 2015.
This article represents a clinically oriented narrative 
review of currently available evidence, first including ran-
domized controlled studies and open-label studies, followed 
by observational ones. We concluded reporting evidence in 
specific populations, that is, first-episode or recent-onset 
schizophrenia, and refractory or treatment-resistant schizo-
phrenia (TRS).
Results
Although several studies on schizophrenia patients’ function-
ing and QOL have been performed, the quantity of available 
data still varies greatly depending on the SGA-LAI under 
investigation.
Risperidone LAi
See Table 1 for the effects of risperidone LAI (RLAI) on 
functioning and QOL.
RCTs and open-label studies
Stable patients
Significant improvements were induced by RLAI in five 
of the 36-item Short Form Health Survey (SF-36) domains 
(emotional role, bodily pain, social functioning, general 
health, and mental health) after 8 weeks and in all SF-36 
domains after 12 weeks, when compared with placebo (the 
US general population).63 These results are in line with those 
of Fleischhacker et al,64 who reported an improvement of 
SF-36 after 12 months of RLAI treatment.
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A cross-sectional study highlighted higher scores in 
30 patients on RLAI concerning social activities and satis-
faction with themselves, their health, and sleep, when com-
pared to 30 patients treated with haloperidol depot, with no 
statistically significant difference found in the QOL scales 
(social functioning scale, satisfaction with life scale, and 
the short version of World Health Organization QOL scale 
[WHO-QoL-BREF]).65
Hospitalized stable patients
In a 12-week randomized, single-blind study, 50 inpatients 
with stable schizophrenia, previously treated with oral 
risperidone for at least 3 months, were randomized to the 
RLAI and oral risperidone groups.66 Patients in the RLAI 
arm displayed significantly higher scores on SF-36 social 
life domains, improvement of side effects, and reduced 
prolactin levels.
In a multicenter, open-label, single-arm study, 
184 patients were treated with RLAI; they got significantly 
better over 12 weeks, as reflected by the finding that 53.2% 
of patients were considered as “not ill” or “borderline ill” at 
the endpoint, when compared to 5.9% at baseline.67 SF-36 
scale got better in all domains except one, consisting in 
bodily pain.
Osborne et al68 reported that an increasing time interval 
between LAI injections (3-month interval vs 2- and 4-weeks 
intervals) was associated with the highest QOL scores.
Unstable patients
On the other hand, a comparative clinical trial indicated 
that RLAI was not superior to oral antipsychotics when 
Heinrichs–Carpenter Quality of Life Scale (QLS), Personal 
and Social Performance Scale (PSP), and self-reported Qual-
ity of Well-Being scale were used to assess QOL and func-
tioning in unstable patients with schizophrenia.69 This was 
confirmed by a naturalistic study conducted in 71 inpatients 
of three psychiatric hospitals in Aquitaine, who were unstable 
or considered to be noncompliant with their pharmacologi-
cal treatment. Even though 46% patients treated with RLAI 
“strongly” to “very strongly” improved on Clinical Global 
Impression Scale (CGI-S) after 6 months, patients claimed 
that their QOL, as assessed by the Tableau d’évaluation 
assistée de qualité de vie, did not change, when compared 
with baseline.70 A long-term randomized trial of 187 unstable 
patients with schizophrenia who had been hospitalized within 
the past 2 years or judged to be at risk for hospitalization 
because of increasing psychiatric service use found no benefit 
of RLAI as compared with oral antipsychotics in preventing 
or delaying time to psychiatric hospitalizations or on QOL 
as assessed through QLS after 2 years.71
Only in a recent study on 9 patients out of 27 nonadher-
ent patients switched to RLAI, an improvement of QOL and 
wellness was demonstrated by the increase in mean values 
of Subjective Well-being Under Neuroleptic Treatment 
scale and Schizophrenia Quality of Life scales after 8 and 
18 months of treatment, respectively, that was simultaneous 
with the control of symptomatology.61
Switching therapy
Two international trials have been conducted in this field 
of research.
In the Switch To Risperidone Microspheres (StoRMi) 
trial, an international, 6-month, open-label trial on patients 
with schizophrenia who were switched from oral or first-
generation antipsychotic-LAI to RLAI for lack of efficacy, 
side effects, or noncompliance, improvements were observed 
in Positive and Negative Syndrome Scale (PANSS) total and 
subscale scores, Global Assessment of Functioning (GAF), 
QOL, treatment satisfaction, and hospitalization.72 Moreover, 
patients showed an overall amelioration of QOL related to 
the health status and a significant increase in fields such as 
mental health, vitality, social activities, and role limitations 
secondary to emotional status.73 These results were confirmed 
in a third subanalysis of the StoRMi trial74 on 842 patients 
with predominantly negative symptoms at baseline (PANSS 
negative subscale score $21) and in fourth post hoc analysis 
in 52 elderly patients ($65 years).75 In a fifth separate analy-
sis from the StoRMi trial on 529 patients76 after 18 months, 
33% of patients achieved symptomatic remission for at least 
6 months; predictors of best outcome (21% of patients) were 
baseline symptom severity, baseline functioning, country, 
schizophrenia type, and early positive treatment course. 
In another subgroup analysis of the StoRMi trial, further 
improvement in symptom control, GAF scores, and SF-36 
mental component summary score could be seen after a 
change to RLAI in 568 clinically stable patients previously 
treated with oral risperidone.77
In a second international, nonrandomized trial following 
unsatisfactory treatment with oral antipsychotics, 182 UK 
patients with schizophrenia or other psychotic disorders, 
symptomatically stable on antipsychotic medication, were 
switched to RLAI. Compared with baseline, significant 
improvement over 6 months was observed concerning ill-
ness severity (PANSS total and subscale scores), patient 
functioning (GAF), health-related QOL, and patient 
satisfaction.78
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These results are confirmed by other studies conducted in 
France,79 Italy,80 Japan,81 and Korea,82 with longer follow-up 
(52 weeks),80 associated with psychosocial intervention.81
In a French study, 202 adults with schizophrenia or other 
psychotic disorders, who were clinically stable for 1 month 
or more on their previous medication (SGA [65%], depot 
[34%], and oral [9%] conventional neuroleptics) and requir-
ing a change of treatment, were directly switched to LRAIs 
and experienced statistically significant improvement of 
disease symptoms, patient functioning (GAF), movement 
disorders, health-related QOL (SF-36), and patient satis-
faction with treatment after 6 months.79 Similar findings as 
regards PANSS total and subscales, GAF, and CGI-S scores 
have been found in a 52-week, open-label prospective trial 
on 347 stable patients switching directly to RLAI from any 
previous antipsychotics.80
In a clinical trial assessing the effectiveness of add-on 
Comprehensive Psycho-educational Approach and Scheme 
Set in 96 Japanese patients with schizophrenia treated with 
RLAI, 80% of patients showed significant improvements in 
Brief Psychiatric Rating Scale (BPRS) negative and general 
subscale scores, and GAF from baseline to 6 months.81 An 
open-label, 48-week, prospective study on 522 patients with 
schizophrenia or schizoaffective disorder from 63 centers in 
South Korea highlighted clinical improvements in symptom 
severity (PANSS, CGI-S) and QOL (Schizophrenia Quality 
of Life scale).82
Two studies focused only on olanzapine-pretreated 
patients or risperidone-pretreated patients. In the first one, 
134 patients out of 192 who were previously treated with 
olanzapine and receiving RLAI without a run-in period 
of oral risperidone completed the study.58 Treatment with 
RLAI was also associated with significant improvements 
in GAF, patient satisfaction with treatment, and SF-36. In 
the second, open-label study on 206 stable patients receiv-
ing oral risperidone or other SGA (olanzapine, quetiapine, 
amisulpride, ziprasidone) and being switched to RLAI for 
12 weeks, patients pretreated with other SGA showed a 
stronger clinical benefit, improved satisfaction, and QOL 
from direct transition to RLAI, as compared with those previ-
ously treated with oral risperidone.83 However, a randomized, 
controlled, open-label study involving individuals affected 
by schizophrenia or schizoaffective disorder showed that 
RLAI and oral olanzapine induced comparable mean scores 
of the Wisconsin Quality of Life Index.84
Observational studies
The 2-year, prospective, observational, electronic Schizo-
phrenia Treatment Adherence Registry (e-STAR) revealed 
that as compared with oral olanzapine or oral risperidone, 
RLAI produced better treatment retention and greater 
improvement in clinical symptoms and functioning in 
1,345 patients with schizophrenia in Spain.85
Data from the Australian cohort of e-STAR showed, 
throughout a 24-month period, that initiation of RLAI was 
associated with improved patient functioning and illness 
severity in 784 patients with schizophrenia or schizoaffective 
disorder. During the entire study, improved outcomes have 
been observed early, which had sustained.86
Macfadden et al87 performed a 24-month, prospective, 
observational study involving 532 patients with schizophre-
nia, during which they evaluated the effectiveness of RLAI 
on QOL, daily functioning, and health status. Two hundred 
and nine of them (39.3%) concluded the study and 305 
(57.3%) had at least 12 months of follow-up data, which 
showed improvements in GAF, Strauss–Carpenter Levels of 
Functioning, PSP, and health status within 3 months, which 
continued over a period of 24 months.
Treatment with RLAI was associated with better QOL 
outcomes (as measured by the EuroQol [EQ]-5D, question-
naire) and lower caregiver burden, compared to other types of 
antipsychotics (oral conventional antipsychotics, injectable 
conventional antipsychotics, and oral SGA) in 1,865 Spanish 
patients with schizophrenia.88
Paliperidone palmitate
One multicenter, 8-week randomized, double-blind, 
placebo-controlled trial showed significant improvement 
with paliperidone palmitate (PP) versus placebo in QOL and 
SF-36 total and subscale scores in 404 adult inpatients with 
schizophrenia.89
Another clinical trial involving acutely symptomatic 
schizophrenic individuals found that functioning improve-
ment could be detected following a 13-week treatment with 
50 or 100 mg equivalents of PP.90 A post hoc analysis that 
specifically aimed to assess the onset of efficacy of PP in 
markedly to severely ill patients with schizophrenia showed 
that PSP scores improved significantly (vs placebo) following 
a 13-week treatment with 75 or 100 mg equivalents of PP, 
but not with a dose of 25 mg.91 A 1-year open-label extension 
of a double-blind study involving 388 adult patients with 
schizophrenia showed that PP improved PSP scores during 
long-term therapy.92 Improvements in the WHO-QoL-BREF 
were also found in elderly patients.93
One clinical analysis reported that the highest tested 
doses of PP (100 and 150 mg) induced significant improve-
ments (vs placebo) in functioning scores of patients with 
schizophrenia who did not respond to a recent treatment with 
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oral risperidone.94 However, comparative analyses indicated 
that PSP scores of individuals with schizophrenia receiving 
short-term PP therapy were not different from those observed 
in patients treated with oral risperidone during initiation of 
RLAI treatment.95
Two noninferiority analyses comparing PP and RLAI 
indicated that the two drugs induce comparable increases of 
PSP scores in schizophrenic patients.96,97 However, PP was 
found to be inferior to RLAI in controlling schizophrenia 
symptoms, when a suboptimal initiation protocol of PP was 
applied.98 PALMFlexS (Paliperidone Palmitate Flexible Dos-
ing in Schizophrenia) study, a prospective, multicenter, open-
label, 6-month, Phase IIIb interventional study, involved 
patients affected by schizophrenia to evaluate the effective-
ness of antipsychotic therapy. In this study, 231 patients, not 
in an acute phase of illness, but with symptomatic schizo-
phrenia, have switched from conventional depot antipsychot-
ics to flexibly dosed PP due to the unsuccessfulness of the 
previous treatment with conventional depot antipsychotics.99 
After switching to PP, more than 50% of all patients reached 
$20% and one-third of all patients reached $50% improve-
ment in PANSS total score. This study highlighted relevant 
improvements in symptom intensity across the groups, which 
has been evaluated by CGI-S, subjective wellness, medica-
tion satisfaction, and patient functioning with PP.
Olanzapine long-acting
During a 8-week randomized, double-blind, placebo-
controlled trial, different dosages of olanzapine long-acting 
(OLAI) (OLAI 210 mg/2 weeks; OLAI 300 mg/2 weeks; 
OLAI 405 mg/4 weeks) induced significant ameliorations 
in the QLS total scores and Mental Health Scale of 404 
inpatients when compared with placebo.100 Also, OLAI 
210 mg/2 weeks, 300 mg/2 weeks, and the combined OLAI 
group were considered to be more effective than placebo on 
the Interpersonal Relations subdomain. The 300 mg/2 weeks 
group and the combined OLAI group were also considered 
to be more effective than placebo on the Instrumental Role 
subdomain. In SF-36, the 300 mg/2 weeks and 405 mg/4 
weeks OLAI groups and the combined OLAI group were 
also considered to be more effective than placebo on the 
mental component score.
OLAI was also tested in a long-term randomized study 
that was aimed to verify the efficacy of this drug formula-
tion in maintenance therapy for patients with schizophrenia. 
The study indicated that patient QOL was significantly 
improved following OLAI treatment.101 An analysis of data 
from three clinical trials involving patients with schizophre-
nia using OLAI as maintenance treatment revealed that most 
of all patients treated with OLAI remained in a steady state 
or improved (62% at 6 months and 52% at 12 months) their 
symptom and functioning levels.102 The study also revealed 
that ,8% of schizophrenia patients have had a worsening in 
symptoms or functioning. However, comparisons between 
oral olanzapine and OLAI indicated that patients experienced 
an increased QOL regardless of being assigned to OLAI or 
oral olanzapine experimental treatment groups.
There is also a secondary analysis of data received from 
a multicenter, randomized, open-label, 2-year study that 
compared the long-term therapeutic efficacy of monthly 
OLAI (405 mg/4 weeks; n=264) with daily oral olanzapine 
(10 mg/day; n=260). In this study, outpatients affected by 
schizophrenia remained stable or improved their positive 
baseline level of functioning over time.103
Moreover, a 6-year, single-arm, open-label extension 
study of OLAI performed at 127 sites in 25 different countries 
on 931 patients, which have been previously enlisted in one 
of three clinical trials of OLAI, showed that patient satisfac-
tion with OLAI was high.104
Aripiprazole long-acting
In a 12-week, randomized, double-blind, placebo-controlled 
study on 340 schizophrenia patients, Kane et al105 reported 
that at week 10, both psychopathology and functioning (PSP) 
improved, compared to placebo. Patient functioning, as eval-
uated by the PSP scale, remained in a steady state in stable 
patients receiving aripiprazole once-monthly (AOM) in two 
pivotal relapse studies.106 In the 52-week study, 403 patients 
previously treated with AOM 400 mg were randomized to get 
AOM 400 mg (n=269) or placebo (n=134). In the 38-week 
study, 662 patients previously treated with oral aripiprazole 
were randomized to get AOM 400 mg (n=265), oral aripipra-
zole (n=266), or AOM 50 mg (subtherapeutic dose; n=131). 
In the first study, there were relevant changes for the worse 
from baseline with placebo compared with AOM 400 mg in 
PSP total score and domain scores for Personal and Social 
Relationships, Self-Care, and Disturbing and Aggressive 
Behavior. In the second study, there were relevant changes 
for the worse from baseline with AOM 50 mg compared with 
AOM 400 mg in PSP total score and the Personal and Social 
Relationships domain score.
The QUAlity of LIfe with AbiliFY Maintena® study is the 
first open-label, rater-blinded, head-to-head study comparing 
two different SGA-LAIs on health-related QOL and function-
ing in 295 patients.107 A statistically significant variation from 
baseline to week 28 on QLS total score demonstrated that 
AOM is more effective than PP. Moreover, in predefined 
analyses, significantly greater improvement with AOM versus 
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PP was consistently demonstrated in patients ,35 years, 
indicating that younger patients may benefit, in particular, 
from AOM 400 mg, when compared to PP.
First-episode or recent-onset 
schizophrenia
A few studies on only RLAI use in early stage of schizo-
phrenia have been performed (see two recent reviews108,109). 
Moreover, specific post hoc analyses have examined patients 
with recent-onset schizophrenia. In this review, we will 
report only the studies including patient functioning and/or 
QOL measures.
In a 6-month open-label study by Parellada et al,110 
382 patients affected by schizophrenia and schizoaffective 
disorder with a disease duration of ,3 years (84% with a 
median duration of 1 year) were administered RLAI, without 
an oral risperidone run-in phase; 40% of them (out of 73% 
that completed the study) showed a 20% improvement on 
total PANSS. Moreover, overall functioning (GAF), quality 
of life (QLS), and satisfaction significantly improved.
In an open-label trial lasting 50 weeks, 64% out of 66 
stable young adults with early schizophrenia or schizoaffec-
tive illness completed the trial, showing clinical improvement 
($20% reduction in PANSS total scores).111 Patient-rated 
QOL (SF-36 scores) and patients’ attitudes toward the medi-
cation (Drug attitude inventory scores) improved throughout 
the trial. Similar findings also emerged in the population of 
older patients.
A prospective, naturalistic, controlled, open-label study 
over 2 years in 50 patients with first-episode schizophrenia 
demonstrated fewer relapses, longer periods of compliance, 
and higher rates of compliance in patients treated with RLAI 
(n=22), when compared with those treated with oral risperi-
done (n=28) (68% vs 32%).112 RLAI was significantly more 
effective in reducing scores on the PANSS (10% vs 2%) and 
in the CGI-S scale (10% vs 2.5%). Lastly, patients treated 
with RLAI showed a greater functional improvement (26% 
increase in the final GAF score), as compared with patients 
on oral risperidone (0.5% increase in the final GAF score).
In a single-site, open-label study lasting 2 years, 
50 patients with schizophreniform disorder or schizophrenia 
were treated with RLAI.113 Of those achieving remission 
according to Remission in Schizophrenia Working Group 
criteria (64%), 97% maintained this status until the end of 
the study, together with greater improvements in social and 
occupational functioning.
Significant improvements from baseline to endpoint were 
found in the PANSS, CGI-S, GAF, and SF-36 in 294 patients 
with a recent onset of schizophrenia treated with RLAI in an 
open-label, 6-month study.114
In a 6-month, open-label, multicenter, Phase IV trial 
recruiting 294 recent-onset schizophrenia patients treated 
with flexible doses of RLAI, patients with good premorbid 
functioning as assessed by Premorbid Adjustment Scale 
(n=142) showed better treatment response (PANSS, CGI-S 
scale, GAF scale, and SF-36), as compared with patients with 
stable-poor (n=116) and deteriorating premorbid function-
ing (n=36).
Clinical improvement (CGI-S), together with good reinte-
gration rate, scarce relapses, or rehospitalization and improved 
social functioning (GAF) were observed in 25 patients 
firstly hospitalized for schizophrenia and treated with RLAI 
along with reintegration methods.115 Bimonthly injection 
associated with psychosocial methods improved interactive 
follow-up, thus enhancing patients’ adherence to medication 
prescriptions.
The post hoc analyses of two observational studies (Trial 
for the Initiation and Maintenance Of REmission in Schizo-
phrenia with risperidone and eSTAR) revealed that among 
patients on RLAI, those recently diagnosed (n=155 with a 
disease duration of ,3 years) showed improvement in their 
severity of illness (CGI-S), baseline level of functioning 
(GAF), and length of hospitalization, when compared with 
patients long-term diagnosed (n=253) at 12- and 24-month 
follow-up.116
Lastly, we found only one study using PP in patients 
with recent-onset schizophrenia (within 1–5 years).117 This 
24-month, rater-blinded, randomized controlled study found 
that time to relapse was significantly longer in patients 
on PP (n=352) versus patients treated with antipsychotic 
monotherapy (n=363). Significantly fewer patients receiving 
PP met the relapse criteria, representing a 29.4% relative 
risk reduction compared with the oral antipsychotics arm. 
However, significant improvements in PSP total score, SF-36, 
EQ-5D, and Subjective Well-being Under Neuroleptic Treat-
ment scale scores were observed in both treatment arms, with 
no significant differences observed between groups, except 
for a significantly greater improvement in EQ-5D index score 
in favor of oral antipsychotics at month 12.
Refractory or TRS
Evidence regarding a significant benefit with antipsychotics 
other than clozapine is still rather limited. LAIs are frequently 
utilized in conjugation with various oral antipsychotics.118 
However, to the best of our knowledge, only two stud-
ies evaluated functioning. In the first one, a multicenter, 
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prospective, 12-month follow-up observational study119 
conducted in 94 patients with TRS treated with RLAI, GAF 
scores significantly increased in both groups of patients, the 
one with dopamine supersensitivity psychosis and the other 
one without. In the second one, a 6-month, outpatient, double-
blind, multicenter trial conducted in 160 TRS patients, RLAI 
50 or 100 mg biweekly produced clinically significant and 
equivalent improvement in PANSS total, positive, and nega-
tive scores, as well as global and functional measures.120
Discussion
So far, published data about the influence of LAIs (apart from 
RLAI) on functioning and QOL in patients with schizophre-
nia seem to be lacking, in terms of either quality or quantity. 
Most of the studies on the newer and recently released 
LAIs (OLAI, PP, AOM) are just focused on analyzing their 
efficacy and side effects profile; the few studies that inves-
tigate patients’ QOL and functioning show methodological 
shortcomings.
First, the instruments used in the available studies do not 
ensure appropriate psychometrics and cannot be applied to 
various stages of the disease. Sometimes they are either too 
lengthy and prove the poor cognitive ability of patients with 
schizophrenia, or are too short to be meaningful.
Second, in terms of duration, clinical trials over a period 
of 6–8 weeks are too short to produce definitive results about 
the possible effects of LAIs on social functioning and QOL, 
because such parameters require longer time to change.
Third, improvements in social, occupational, and voca-
tional functioning cannot be expected only by medication; 
other elements need to be combined in the treatment: eco-
nomic support, educational actions, and real opportunities 
offered in daily life. Such factors have not been adequately 
considered in the design of clinical trials, particularly, when 
multicenter structures (with different levels of resources 
available to ensure extra clinical interventions) were involved 
in the research.
Fourth, analyses conducted over inpatients or outpatients 
have produced different results: patients’ actual clinical 
conditions may have a relevant role on the effects produced 
by SGA-LAIs, but the available studies do not take it appro-
priately into consideration.
Bearing in mind the above-mentioned limitations, the 
available clinical studies do show that SGA-LAIs are effective 
in ameliorating patient functioning and/or QOL of patients 
with schizophrenia, as compared with placebo. Moreover, 
the significant amount of evidence in recently published 
RCTs and open-label studies demonstrates the superiority 
of RLAI versus oral antipsychotics or depot conventional 
antipsychotics as regards patient functioning and QOL in 
stable patients and no additional benefit over oral treatment 
in unstable patients. Furthermore, results from observational 
studies, which are more representative of routine clinical 
practice in a real-world setting, consistently showed the 
superior effectiveness for RLAI versus oral antipsychotics 
on patient functioning and QOL.
A similar efficacy was shown by RLAI and PP in direct 
comparative trials, suggesting that SGA-LAIs sharing a com-
parable receptor binding profile may induce similar effects 
on functioning in patients with schizophrenia.121
Not so much data are present in literature about the 
long-term variations in the functioning of patients with 
schizophrenia treated with OLAI as maintenance therapy, 
and it is not clear whether the observed variations are dif-
ferent from those observed with treatment based on oral 
olanzapine.
As regards AOM, the QUAlity of LIfe with AbiliFY 
Maintena® is the first to use a health-related QOL as a primary 
endpoint to compare two SGA-LAIs and is the first to show 
superiority of one SGA-LAI over another. Moreover, even 
though it was randomized, it was designed to be more natu-
ralistic than traditional pivotal studies, as regards the inclu-
sion criteria, as suggested by the low frequency of screening 
failure (22.6%), indicating that the study did not enroll highly 
selected patients, which is consistent with a naturalistic set-
ting. Lastly, the authors hypothesized that the improvement in 
QOL and patient functioning with AOM 400 versus PP may 
be attributed to the partial agonism at dopamine D2 receptors, 
which are hypothesized to modulate dopaminergic activity in 
the brain, thereby reducing positive symptoms and potentially 
improving negative and cognitive symptoms.
Also, the evidence regarding SGA-LAI use in first-
episode or recent-onset schizophrenia patients is far from 
conclusive, mainly as regards the duration of treatment.
Lastly, as regards the two studies conducted on TRS, it 
should be noted that all the patients of the Japanese study119 
were TRS patients; however, none of them had tried cloza-
pine. Moreover, none of them had problems with treatment 
adherence according to the study criteria.122 As regards the 
study of Meltzer et al,120 although the authors have hypoth-
esized that RLAI 100 mg would be more effective than RLAI 
50 mg, no differences were found in the two groups of treat-
ment. However, an increasing response was found during the 
course of the study, confirming the value of longer clinical 
trial duration for patients with TRS, but not superiority of 
the higher dose.120
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Conclusion
The status of the research on SGA-LAIs is lacking in several 
aspects that may help physicians in choosing the correct 
drug therapy. Meaningful differences have been observed 
between SGA-LAIs in the onset of their clinical efficacy, 
and in the relationships between symptoms and functioning 
scores. Lastly, head-to-head studies comparing the effects 
of SGA-LAIs on classical measures of psychopathology 
and functioning are available, mainly on RLAI, while those 
comparing OLAI with other SGA-LAIs are still lacking.
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